Since the advent of targeted therapy, a game-changer in oncologic management in GC patients with HER2 amplification, for example, trastuzumab, many other related researches to explore the significance of gene amplification in GC rapidly intensified. This evidence concerns the gene ERBB2 and gastric cancer.